Presentation is loading. Please wait.

Presentation is loading. Please wait.

Beckett N, Peters R, Tuomilehto J, et al. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment.

Published byToby Spencer Modified over 9 years ago

Similar presentations

Presentation on theme: "Beckett N, Peters R, Tuomilehto J, et al. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment."— Presentation transcript:

1 Beckett N, Peters R, Tuomilehto J, et al. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial BMJ. 2012;344:d7541 doi: 10.1136/bmj.d7541 (Published 4 January 2012) HYVET 1-year extension: Immediate and late benefits with indapamide SR ± perindopril in the treatment of hypertensive patients.

2 HYVET 1-year extension 1 Study protocol 3.1 years on active treatment 1 year on active treatment n= 3845 patients n= 1712 patients Placebo Indapamide SR ± perindopril Indapamide SR ± perindopril Indapamide SR ± perindopril 2.1 years 1-year extension 2.1 years 1. Beckett N, Peters R, Tuomilehto J, et al. BMJ 2012;344:d7541 doi: 10.1136/bmj.d7541 (Published 4 January 2012) vs.

3 HYVET 1 Results n= 3845 patients Placebo Indapamide SR ± perindopril 2.1 years Stroke hazard ratio: -39% P =0.05 in favor of the indapamide SR ± perindopril group. Heart failure hazard ratio: -64% P<0.001 in favor of the indapamide SR ± perindopril group. All-cause mortality hazard ratio: -21% P=0.02 in favor of the indapamide SR ± perindopril group. 1. Beckett NS, Peters R, Fletcher AE, et al. N Engl J Med. 2008;358:1887-1898. Cardiovascular events hazard ratio: -34% P<0.001 in favor of the indapamide SR ± perindopril group. Cardiovascular mortality hazard ratio: -23% P=0.06 in favor of the indapamide SR ± perindopril group. vs.

4 HYVET 1-year extension 1 Study protocol 3.1 years on active treatment 1 year on active treatment n= 3845 patients n= 1712 patients Placebo Indapamide SR ± perindopril Indapamide SR ± perindopril Indapamide SR ± perindopril 1. Beckett N, Peters R, Tuomilehto J, et al. BMJ 2012;344:d7541 doi: 10.1136/bmj.d7541 (Published 4 January 2012) 2.1 years 1-year extension vs.

5 No significant difference between the two arms in: - Stroke P=0.28 - Heart failure P=0.28 - Cardiovascular events P=0.55 HYVET 1-year extension 1 Results Indapamide SR ± perindopril provides patients with immediate protection against stroke, heart failure, and cardiovascular events These benefits appeared within 1 year of starting treatment Indapamide SR ± perindopril provides patients with immediate protection against stroke, heart failure, and cardiovascular events These benefits appeared within 1 year of starting treatment n= 3845 patients n= 1712 patients Placebo Indapamide SR ± perindopril Indapamide SR ± perindopril Indapamide SR ± perindopril 2.1 years 1-year extension 1. Beckett N, Peters R, Tuomilehto J, et al. BMJ 2012;344:d7541 doi: 10.1136/bmj.d7541 (Published 4 January 2012) vs.

6 Indapamide SR ± perindopril provides cumulative time-dependent life-saving benefits, increased over the long term. Total mortality hazard ratio: -52% P =0.02 in favor of the group treated for 3.1 years. Cardiovascular mortality hazard ratio: -81% P =0.03 in favor of the group treated for 3.1 years. n= 3845 patients n= 1712 patients Placebo Indapamide SR ± perindopril Indapamide SR ± perindopril Indapamide SR ± perindopril 2.1 years 1-year extension HYVET 1-year extension 1 Results 1. Beckett N, Peters R, Tuomilehto J, et al. BMJ 2012;344:d7541 doi: 10.1136/bmj.d7541 (Published 4 January 2012) vs.

7 Indapamide SR ± perindopril provides cumulative time-dependent life-saving benefits, increased over the long term. HYVET 1-year extension 1 Results 1. Beckett N, Peters R, Tuomilehto J, et al. BMJ 2012;344:d7541 doi: 10.1136/bmj.d7541 (Published 4 January 2012) Total mortality Cardiovascular mortality P=0.02 P=0.03 -52% -81%

Download ppt "Beckett N, Peters R, Tuomilehto J, et al. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment."

Similar presentations

CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.

CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.
TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345:1291-7. Incidence of CV events in women.

TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.
Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.

Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
Clinical implications. Burden of coronary disease 56 millions deaths worldwide in 2001 56 millions deaths worldwide in 2001 29% due to CV disease (~ 16.

Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.
Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.

Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.
Is It the Achieved Blood Pressure or Specific Medications that Make a Difference in Outcome, or Is the Question Moot? William C. Cushman, MD Professor,

Is It the Achieved Blood Pressure or Specific Medications that Make a Difference in Outcome, or Is the Question Moot? William C. Cushman, MD Professor,
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results www.shift-study.com Swedberg K, et al. Lancet. 2010;376(9744):875-885.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):
Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)

Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)
CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.

CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.
RALES: Randomized Aldactone Evaluation Study Purpose To determine whether the aldosterone antagonist spironolactone reduces mortality in patients with.

RALES: Randomized Aldactone Evaluation Study Purpose To determine whether the aldosterone antagonist spironolactone reduces mortality in patients with.
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.

AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.
Study Design Scirica BM, Bhatt DL Braunwald et al, Sexagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013.

Study Design Scirica BM, Bhatt DL Braunwald et al, Sexagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med
BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.

BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.
Lancet 373:1765-72, 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.

HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
Renal damage occurs in 1 out of 4 hypertensives Adapted from Leoncini et al. J Hypertens. 2008;26:427-432.

Renal damage occurs in 1 out of 4 hypertensives Adapted from Leoncini et al. J Hypertens. 2008;26:
Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

Similar presentations

Ads by Google